Ticagrelor Compared with Clopidogrel Increased Adenosine and Cyclic Adenosine Monophosphate Plasma Concentration in...

Area of Science:

• Cardiology
• Pharmacology
• Biochemistry

Background:

• Ticagrelor offers superior antiplatelet efficacy compared to clopidogrel.
• Ticagrelor's inhibition of adenosine cellular uptake has potential cardiovascular implications.
• Dual antiplatelet therapy (DAPT) is standard for acute coronary syndrome (ACS).

Purpose of the Study:

• To investigate the relationship between adenosine and cyclic adenosine monophosphate (cAMP) plasma concentrations and the antiplatelet effect of ticagrelor versus clopidogrel.
• To compare the impact of ticagrelor and clopidogrel on adenosine and cAMP levels in ACS patients.

Main Methods:

• Prospective, observational, single-centre cohort study of 68 non-ST-segment elevation ACS patients.
• Measurement of platelet aggregation inhibition (IPA), adenosine, adenosine deaminase (ADA), and cAMP plasma concentrations via immunoassay.
• Data collection included demographics, clinical information, and biochemical assays on admission and 48 hours post-angiography.

Main Results:

• Ticagrelor group exhibited significantly higher mean IPA (93.5%) than the clopidogrel group (67.2%; p=0.000).
• Patients on ticagrelor showed significantly increased plasma adenosine (p=0.029) and cAMP (p=0.037) levels compared to clopidogrel.
• A weak positive correlation was observed between IPA and plasma adenosine (r=0.390, p=0.001) and cAMP (r=0.335, p=0.005).

Conclusions:

• Ticagrelor demonstrates a more potent antiplatelet effect than clopidogrel in ACS patients.
• Ticagrelor significantly increases plasma adenosine and cAMP concentrations, which may contribute to its enhanced antiplatelet activity.
• The findings suggest a link between elevated adenosine/cAMP levels and improved platelet inhibition with ticagrelor therapy.